Publication | Closed Access

Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial

In-hospital ProcalcitoninVeryfing Dyspnea TrialCardiovascular DiseaseMid-regional Pro-adrenomedullin TestingPulmonary MedicineMedicineEmergency MedicineHospital Medicine